Trump's First 100 Days, Part IV: AMCs, Life Sciences, Pharma, and Medical Device Companies

The incoming Trump Administration's policies could have a great and lasting impact on the Affordable Care Act. This four-part webinar series will look at these potential impacts on numerous groups, including providers, payers, the uninsured, those on Medicare or Medicaid, and medical device companies, among others.

In Trump's first 100 days, the 21st Century Cures Act, existing regulatory and research priorities, and expected administrative changes will all impact the research and life science community. Part IV will discuss the key areas of expected change and implementation challenges under a new Administration.

To register, please click here.